Type(s) of breast cancer-Atypical Lobular Hyperplasia Posts on Medivizor
Navigation Menu

Type(s) of breast cancer-Atypical Lobular Hyperplasia Posts on Medivizor

Looking for patients with metastatic triple negative breast cancer to examine the effect of Nivolumab in combination with Cabozantinib

Posted by on Feb 3, 2018 in Breast cancer | 0 comments

In a nutshell This trial is examining the effectiveness of nivolumab (Opdivo) in combination with cabozantinib (Cometriq) for metastatic triple-negative breast cancer (cancer that is not dependent on hormones or HER2 for growth). The outcome to be measured will be the response rate of the cancer to this treatment. This study is...

Read More

Some traits of lobular in-situ neoplasia can predict the risk of developing invasive breast cancer

Posted by on Aug 26, 2013 in Breast cancer | 0 comments

In a nutshell In this study researchers investigated which traits of lobular in-situ neoplasia (LN) are likely to predict upgrade to invasive breast cancer. Some background LN is the presence of abnormal cells in the lobules (milk-producing glands) of the breast. LN includes 2 conditions which are considered to increase the risk of developing...

Read More

Recurrence of breast cancer in the central nervous system (CNS) associated with trastuzumab treatment

Posted by on Jul 20, 2013 in Breast cancer | 0 comments

In a nutshell This large analysis determined the risk of CNS metastases as the first site of recurrence in patients with HER2-positive breast cancer who received trastuzumab (herceptin). Some background Breast cancer recurrence (return of the cancer) may occur near the site of the original cancer, or at other distant locations. The central nervous...

Read More

Tamoxifen can be used as preventive agent for women at high risk of breast cancer

Posted by on Mar 4, 2013 in Breast cancer | 0 comments

In a nutshell Tamoxifen is one of the main drugs used for hormonal treatment of breast cancer. The aim of this article was to establish the value of Tamoxifen as a preventive agent for women who have high chances of developing breast cancer. Main finding: Tamoxifen notably reduces the risk of developing breast cancer in easily identifiable higher risk...

Read More